NCT00820911 - Efficacy and Safety of AEB071 Versus Cyclosporine in de Novo Renal Transplant Recipients | Biotech Hunter

Enrollment

175

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions

Kidney Transplantation

Interventions

DRUG

cyclosporine (reduced exposure) / everolimus

twice daily

DRUG

AEB071 300 mg b.i.d. / everolimus

twice daily

DRUG

AEB071 200 mg b.i.d. / everolimus

twice daily

Trial Locations (28)

2050

Novartis Investigative Site, Camperdown

3168

Novartis Investigative Site, Clayton

5011

Novartis Investigative Site, Woodville

8091

Novartis Investigative Site, Zurich

9000

Novartis Investigative Site, Ghent

10002

Novartis Investigative Site, Taipei

10117

Novartis Investigative Site, Berlin

20122

Novartis Investigative Site, Milan

20162

Novartis Investigative Site, Milan

28034

Novartis Investigative Site, Madrid

29200

Novartis Investigative Site, Brest

31054

Novartis Investigative Site, Toulouse

44035

Novartis Investigative Site, Nantes

69120

Novartis Investigative Site, Heidelberg

119074

Novartis Investigative Site, Singapore

C1107BEA

Novartis Investigative Site, San Martín

X5022CPU

Novartis Investigative Site, Córdoba

A-6020

Novartis Investigative Site, Innsbruck

90020-090

Novartis Investigative Site, Porto Alegre

04023-900

Novartis Investigative Site, São Paulo

Unknown

Novartis Investigative Site, Bogotá

Novartis Investigative Site, Santiago de Cali

140 00

Novartis Investigative Site, Prague

3015 CE

Novartis Investigative Site, Rotterdam

0424

Novartis Investigative Site, Oslo

041 90

Novartis Investigative Site, Košice

975 17

Novartis Investigative Site, Banská Bystrica

08907

Novartis Investigative Site, L'Hospitalet de Llobregat